Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aldeyra Therapeu (NQ: ALDX ) 3.990 -0.080 (-1.97%) Streaming Delayed Price Updated: 11:47 AM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Aldeyra Therapeu < Previous 1 2 3 4 5 6 Next > Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable June 20, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease June 13, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Host Investor Roundtable Q&A June 12, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference May 29, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease May 08, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day April 25, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 April 18, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease March 28, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm February 09, 2024 From Bragar Eagel & Squire Via GlobeNewswire Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 06, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases January 04, 2024 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis December 19, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis December 18, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease November 27, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is One of Wednesday Morning’s Most Active Stocks November 01, 2023 Via Investor Brand Network Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap November 01, 2023 From Aldeyra Therapeutics, Inc. Via Business Wire NASDAQ:ALDX Long Term Investor Alert: Investigation over Potential Wrongdoing at Aldeyra Therapeutics, Inc. October 17, 2023 San Diego, CA -- (SBWIRE) -- 10/17/2023 -- Certain directors of Aldeyra Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties. Via SBWire DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX September 29, 2023 WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March... Via TheNewswire.com Topics Lawsuit Exposures Financial Legal DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX September 29, 2023 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX) September 28, 2023 From The Law Offices of Frank R. Cruz Via Business Wire ALDEYRA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm September 27, 2023 From Bragar Eagel & Squire, P.C. Via Business Wire Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit September 26, 2023 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire NASDAQ: ALDX Investor Alert: Deadline on September 29, 2023 in Lawsuit Against Aldeyra Therapeutics, Inc. September 25, 2023 San Diego, CA -- (SBWIRE) -- 09/25/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 29, 2023 in the lawsuit filed for certain investors of Aldeyra Therapeutics,... Via SBWire Topics Lawsuit Exposures Financial Legal ALDX DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action – ALDX September 25, 2023 From The Rosen Law Firm PA Via GlobeNewswire ALDX FINAL DEADLINE FRIDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX September 23, 2023 WHY: NEW YORK, NY - (NewMediaWire) - September 23, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March... Via TheNewswire.com Topics Lawsuit Exposures Financial Legal ALDX FINAL DEADLINE FRIDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX September 23, 2023 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aldeyra, RTX, and Eos and Encourages Investors to Contact the Firm September 22, 2023 From Bragar Eagel & Squire Via GlobeNewswire ALDX DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX September 22, 2023 WHY: NEW YORK, NY - (NewMediaWire) - September 21, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March... Via TheNewswire.com Topics Lawsuit Exposures Financial Legal ALDX DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX September 21, 2023 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX September 18, 2023 WHY: NEW YORK, NY - (NewMediaWire) - September 18, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March... Via TheNewswire.com Topics Lawsuit Exposures Financial Legal < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.